Vor Biopharma

Update in progress

VOR (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Vor Biopharma Inc. is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases. It is advancing telitacicept, a fusion protein for generalized myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, and IgA nephropathy. The company has a license with RemeGen Co., Ltd. to develop and commercialize telitacicept and related products. Founded in 2015, it is based in Boston, Massachusetts.

Company score

Sentiment: 0.06; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.00; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.03; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive